Trump Orders Fast-Tracking Of Psychedelic Research For Veterans’ PTSD Treatment
President Donald Trump signed an executive order Saturday to accelerate research into psychedelic treatments, specifically focusing on ibogaine as a potential therapy for veterans suffering from Post-Traumatic Stress Disorder and traumatic brain injuries.
The order aims to remove long-standing regulatory barriers that have limited large-scale study of ibogaine, which is currently classified as a Schedule I controlled substance in the United States. Officials say the move will allow expanded clinical trials and faster evaluation of the drug’s medical potential.
Under the directive, the Food and Drug Administration will establish new protocols for the safe therapeutic use of psychedelics, while federal agencies will increase coordination and data sharing related to ongoing research.
Trump said the goal is to provide new options for veterans dealing with severe mental health conditions. “Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives,” he said, emphasizing the need for alternative treatments beyond traditional medications.
Mehmet Oz described the move as a major shift in how the U.S. approaches mental health care, particularly for patients who have not responded to standard treatments. He suggested psychedelic therapies could offer new pathways for recovery in cases involving depression, addiction, and trauma-related disorders.
Early research has suggested ibogaine may help reduce symptoms tied to addiction and PTSD, though scientists stress that more rigorous studies are needed to confirm safety and effectiveness. The order is expected to significantly expand those efforts.
The initiative has drawn support from figures including Joe Rogan, who has highlighted anecdotal success stories from veterans, as well as former policymakers across party lines.
Federal officials indicated that, pending regulatory approval, government-backed treatment programs involving psychedelic therapies could begin as soon as this summer.